EUCTR2010-023356-90-DK进行中（未招募）不适用
Electrochemotherapy as a palliative treatment for brain metastases
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients > 18 years.
- •2.ECOG performance status < 2.
- •3.Diagnosis of brain metastases originated from histological or cytological verified cancer of any histology.
- •4.Patients should have received whole-brain radiation therapy (WBRT) with a time interval of at least 2 months from completion of WBRT until inclusion in this study.
- •5.Patients must have been offered every available standard treatment. If there is no more standard treatment available or if a patient does not wish to receive the standard treatment, the patient can be included in this study.
- •6.Endocrine anti-cancer treatment may be continued if the patient can benefit from this treatment i.e. obtain or gain control of the cancer outside the brain.
- •7.Ongoing chemotherapy that has had no effect on the present brain metastases may be continued. However, no chemotherapy should be given 3 weeks prior to and 2 weeks after treatment with electrochemotherapy.
- •8.Patients can be initiated on chemotherapy during this study as long as the treatment has no documented effect on brain metastases.
- •9.Local surgery or radiotherapy of a palliative nature and with no documented effect on brain metastases can be performed during the study.
- •10.Brain metastases to be treated must be > 10 millimetre and < 27 millimetre.
- •11.Brain metastases to be treated must be accessible for treatment. This assessment is performed by a neurosurgeon using a MRI scan of the brain.
- •12.Patients may have more brain metastases than are being treated.
- •13.Estimated remaining life time must be more than 3 months.
- •14.Patients must have adequate organ functions:
- •oAdequate bone marrow reserve: Leucocytes (WBC) > 3.0 x 109/l, thrombocytes > 75 x 109/l, hemoglobin > 7 g/dl.
- •oHepatic: Alkaline phosphate, ALAT or ASAT and bilirubin must not be increased more than 2 times, pp > 40, APTT in normal range. Medical correction is allowed, e.g. correction of low pp using vitamin K.
- •oRenal: if creatinin > 150 micromolar do a GFR examination (Chrom-EDTA). If Chrom-EDTA clearance is less than 48 ml/min, treatment cannot be offered
- •15.Patients must not have a blood pressure (BP) over 180 mm Hg systolic and 110 mm Hg diastolic. In the case of BP>180/110 mm Hg, this can be medically corrected, and the patient can be included, when the BP is below this threshold.
- •16.Sexually active men and women of childbearing potential must use adequate birth control during this study and 6 month after the administration of bleomycin (contraceptive pills, intrauterine devices, injection of prolonged gestagen, subdermal implantation, hormonal vaginal devices, transdermal patches).
- •17.Participating patients must be able to understand the patient information (‘Deltagerinformation’).
- •18.Participating patients must have signed a written informed consent and power of attorney prior to inclusion in this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Acute lung infection.
- •2.Previous bleomycin treatment with more than 200.000 Units/m2.
- •3.Previous allergic reaction to bleomycin.
- •4.Allergy towards the sedation used.
- •5.Pregnancy or breastfeeding. Pregnancy in fertile women is excluded by a measurement of HCG in a blood sample. Sterile or infertile women are excluded from the requirement to use anticonception. To be considered sterile or infertile, the patient must have undergone surgical sterilization (vasectomy/bilateral tubectomy, hysterectomy and bilateral ovarectomy) or be post-menopausal defined as the absence of menstruation.
- •6.Treatment with G-CSF (Granulocyte Colony Stimulating Factor) or other cytokines.
- •7.Lung diffusion capacity (DLCO) below normal. DLCO is to be performed in case of suspected (anamnestic or clinical) reduced lung function.
- •8.Physician’s assessment that meningeal carcinomatosis (leptomeningeal disease) is a likely cause of the patient’s symptoms.
- •9.Treatment with anticoagulants (marevan, marcumar, innohep). If the physician finds it safe to pause the administration of anticoagulants the patient can be included. This decision should be made using the Neurosurgery Department’s Guideline.
- •10.Allergic to nickel, chromium or cobalt.
- •11.Participation in another clinical study with an experimental drug up to 4 weeks prior to inclusion.
- •12.Illnesses, medical, social or physiological, that may affect the patient’s ability to understand the patient information and participate in the follow-up.
- •13.Other serious systemic illnesses (i.e. active infection, abnormal EKG) that the investigator finds may affect the patient’s safety and/or ability to complete the study.
- •14.Treatment with Immunosuppressant drugs such as methotrexat and cyclosporine during the study. Treatment with prednisolone is accepted during the study.
- •15.Implanted pacemaker, defibrillators or hearth valve prosthetics.
- •16.Implanted devices such as neurostimulators, eartransplants, insulinpump, metallic tracheostomy.
- •17.Catheters with metal such as Port á cath, Swan Ganz, P-dialysis cath., ventriculoartrial and -peritoenal shunts, bladder cath. with thermo measurement.
- •18.Metallic clips/prosthetics/magnets from surgery such as neuro- or abdominal clips, tooth- or other prosthetics.
- •19.Disorganised metallic material such as metal fragments in the eyes, shrapnel, gun shot injuries.
研究者
相似试验
招募中
2 期
Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlled trial (ECT-HN)2025-520735-16-00IRCCS Istituto Nazionale Tumori Fondazione Pascale96
已完成
不适用
EURECA (European research on electrochemotherapy in head and neck cancer) projectRecurrent, metastatic HN cancer or primary cancer in patients with severe co-morbidities and/or which only regular treatment with extensive morbidity is availableCancerISRCTN78463063IRCCS Policlinico San Matteo Foundation (Italy)120
已完成
2 期
Electrosclerotherapy as a novel treatment option for capillary malformations: a pilot studyCapillary malformationsport-wine stains10005330NL-OMON45598Academisch Medisch Centrum20
尚未招募
1 期
Cancer treatment using electrical pulses and chemotherapy agentIRCT20230403057807N1Bagheiat-allah University of Medical Sciences120
已完成
2 期
Irreversible electroporation treatment in patients with pancreatic locally advanced adenocarcinomaPancreatic adenocarcinoma100179901001799110017998Pancreatic CancerNL-OMON40224Academisch Medisch Centrum50